GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Float Percentage Of Total Shares Outstanding

Regen BioPharma (Regen BioPharma) Float Percentage Of Total Shares Outstanding : 91.24% (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Regen BioPharma's float shares is 3.75 Mil. Regen BioPharma's total shares outstanding is 4.11 Mil. Regen BioPharma's float percentage of total shares outstanding is 91.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Regen BioPharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Regen BioPharma's Institutional Ownership is 0.00%.

Regen BioPharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Regen BioPharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=3.75/4.11
=91.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma (Regen BioPharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
LIXT PKTX ALRN CVKD MNPR AMTI FRTX XCUR WINT CWBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RGBPP.PFD:USA
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Website
https://www.regenbiopharmainc.com
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.